Glycogen synthase kinase-3 beta (GSK-3β) mRNA (GSK3B mRNA)

Glycogen synthase kinase-3 beta (GSK-3β) mRNA is the transcript of the GSK3B gene, which encodes a proline-directed serine/threonine kinase essential for diverse signaling pathways, including the Wnt/β-catenin and PI3K/Akt pathways (Source: UniProt P49841). Targeting the mRNA via RNA interference (RNAi) or antisense oligonucleotides (ASOs) aims to reduce the total cellular pool of GSK-3β protein, which is often overexpressed or hyperactive in pathological states (Source: PubMed PMC4019731). In Alzheimer's disease, reducing GSK-3β expression via mRNA targeting has been shown to decrease Tau hyperphosphorylation and amyloid plaque formation in preclinical models (Source: PubMed PMID 24732012). Furthermore, GSK-3β is a key regulator of glucose metabolism, and its modulation is explored for treating Type 2 diabetes and certain cancers where it promotes cell survival (Source: PubMed PMC3590256). While small molecule inhibitors exist, targeting the mRNA provides a mechanism to achieve higher isoform specificity and potentially avoid the toxicity associated with broad kinase inhibition. Safety concerns include the risk of oncogenesis due to the stabilization of β-catenin and the challenges of delivering RNA-based therapeutics across the blood-brain barrier (Source: PubMed PMC6337603).

Other names

GSK3B transcriptGlycogen synthase kinase 3 beta messenger RNAGSK-3 beta mRNA

Reduction of GSK-3β protein expression through RNA interference (RNAi) or antisense-mediated mRNA degradation, thereby modulating downstream signaling pathways such as Wnt/beta-catenin and insulin signaling.